Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Receivables - Other: 2020-2025

Historic Receivables - Other for Fulcrum Therapeutics (FULC) over the last 5 years, with Mar 2025 value amounting to $979,000.

  • Fulcrum Therapeutics' Receivables - Other was N/A to $979,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $979,000, marking a year-over-year change of. This contributed to the annual value of $2.1 million for FY2024, which is 290.32% up from last year.
  • Fulcrum Therapeutics' Receivables - Other amounted to $979,000 in Q1 2025, which was down 53.29% from $2.1 million recorded in Q4 2024.
  • In the past 5 years, Fulcrum Therapeutics' Receivables - Other registered a high of $3.7 million during Q3 2024, and its lowest value of $99,000 during Q1 2023.
  • In the last 3 years, Fulcrum Therapeutics' Receivables - Other had a median value of $817,500 in 2023 and averaged $1.4 million.
  • In the last 5 years, Fulcrum Therapeutics' Receivables - Other crashed by 87.66% in 2023 and then soared by 530.34% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Receivables - Other (Quarterly) stood at $1.1 million in 2021, then crashed by 79.86% to $229,000 in 2022, then spiked by 134.50% to $537,000 in 2023, then surged by 290.32% to $2.1 million in 2024, then reached $979,000 in 2025.
  • Its Receivables - Other stands at $979,000 for Q1 2025, versus $2.1 million for Q4 2024 and $3.7 million for Q3 2024.